| 货号 | HV716016 |
|---|---|
| 品牌 | abinScience |
| 种属反应性 | Human |
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| 宿主 | Human |
| 同种型 | IgG4-IgG1, Lambda |
| 表达系统 | Mammalian Cells |
| 克隆类型 | Monoclonal |
| 靶标 | OSMRB, IL-31R subunit beta, Oncostatin-M-specific receptor subunit beta, Interleukin-31 receptor subunit beta, IL-31RB, IL-31R-beta, OSMR, IL-31 receptor subunit beta |
| 内毒素水平 | Please contact the lab for this information. |
| 纯度 | >95% purity as determined by SDS-PAGE. |
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
| Accession号 | Q99650 |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| 别名 | KPL-716, 30C6(N73D), BIIB069, BIIB-069, 2243320-83-2 |
| 背景 | Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash. • Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma., PMID:34087162 • Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease., PMID:28368383 • Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth., PMID:34380633 • Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology., PMID:26198770 • The Role of Oncostatin M and Its Receptor Complexes in Cardiomyocyte Protection, Regeneration, and Failure., PMID:35163735 • Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts., PMID:38717842 • Engineered interleukin-6-derived cytokines recruit artificial receptor complexes and disclose CNTF signaling via the OSMR., PMID:38569939 • AHNAK, regulated by the OSM/OSMR signaling, involved in the development of primary localized cutaneous amyloidosis., PMID:37100691 • Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma., PMID:24659184 • Targeting OSMR in glioma stem cells., PMID:28177884 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
SEC-HPLC detection for Research Grade Vixarelimab.
7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
24小时产品查询
扫一扫关注我们
专属渠道经理
